Each patient's cancer has a specific genetic and molecular signature that may dramatically affect how it will respond to different treatments.
Articles
Personalized Medicine
Future Medicine
The company name, N-of-One, reflects the company's approach to personalized cancer treatment. In a typical clinical trial, the number of patients enrolled ('N') is large, allowing researchers to assess the benefit/risk of an investigational drug in the average patient. Clinical trials rarely reflect real-world medicine where few, if any, cancer patients are 'average'. As cancer research advances, so does the realization that treating patients as if they were average is costly and often neither efficient nor effective. At N-of-One, no patient is 'average'; rather, each patient is the only 'N', a unique individual with a unique cancer.
Future Medicine
The company name, N-of-One, reflects the company's approach to personalized cancer treatment. In a typical clinical trial, the number of patients enrolled ('N') is large, allowing researchers to assess the benefit/risk of an investigational drug in the average patient. Clinical trials rarely reflect real-world medicine where few, if any, cancer patients are 'average'. As cancer research advances, so does the realization that treating patients as if they were average is costly and often neither efficient nor effective. At N-of-One, no patient is 'average'; rather, each patient is the only 'N', a unique individual with a unique cancer.
Pioneering Personalized Cancer Care
Scientific American
The realization that cancer is ultimately a disease of mutated genes has driven cancer researchers to ask how this information can be used to direct specific treatments to individual patients. This query represents one of the newest and most important trends in oncology, personalized medicine. Its core insight is that a physician could improve the treatment of a disease by understanding its molecular biology through well-timed tests of the highest quality and relevance.
READ THE FULL PUBLICATION ►
Scientific American
The realization that cancer is ultimately a disease of mutated genes has driven cancer researchers to ask how this information can be used to direct specific treatments to individual patients. This query represents one of the newest and most important trends in oncology, personalized medicine. Its core insight is that a physician could improve the treatment of a disease by understanding its molecular biology through well-timed tests of the highest quality and relevance.
READ THE FULL PUBLICATION ►
Personalized Medicine - What is Missing?
Report Card on Cancer in Canada
Cancer treatment has changed dramatically over the last few years. It is now not only possible, but also often important to go beyond classifying tumours based on where they occur in the body. In fact, two patients with cancer of the same organ of origin may well have two very different cancers that can require different treatment strategies. Decades of painstaking research have demonstrated that each tumour has a unique set of genetic aberrations and molecular changes. Some of these genetic and molecular characteristics have been termed biomarkers since they can mark how well a tumour will respond to certain treatments or how quickly the disease will progress.
Report Card on Cancer in Canada
Cancer treatment has changed dramatically over the last few years. It is now not only possible, but also often important to go beyond classifying tumours based on where they occur in the body. In fact, two patients with cancer of the same organ of origin may well have two very different cancers that can require different treatment strategies. Decades of painstaking research have demonstrated that each tumour has a unique set of genetic aberrations and molecular changes. Some of these genetic and molecular characteristics have been termed biomarkers since they can mark how well a tumour will respond to certain treatments or how quickly the disease will progress.
